Trials / Completed
CompletedNCT04869800
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-398 in Healthy Volunteers Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
Detailed description
A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-398 in healthy volunteers under fasting conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-398 | Test Drug |
| DRUG | CKD-501, D745 | Reference Drug |
Timeline
- Start date
- 2021-05-27
- Primary completion
- 2021-06-07
- Completion
- 2021-06-15
- First posted
- 2021-05-03
- Last updated
- 2021-08-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04869800. Inclusion in this directory is not an endorsement.